Liver Cancer  >>  Erbitux (cetuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
NCT00142428: Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Completed
2
30
US
Cetuximab
Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Bristol-Myers Squibb
Hepatocellular Carcinoma
10/05
10/08
NCT00483405: Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer

Checkmark P2 data
Nov 2011 - Nov 2011: P2 data
Completed
2
33
US
cetuximab, Erbitux, capecitabine, Xeloda, oxaliplatin, Eloxatin
UNC Lineberger Comprehensive Cancer Center, Sanofi, Roche Pharma AG, Bristol-Myers Squibb, National Center for Research Resources (NCRR), National Cancer Institute (NCI)
Liver Cancer
02/10
12/10

Download Options